Yahoo
NYSE - Nasdaq Real Time Price USD

IQVIA Holdings Inc. (IQV)

279.04 +7.49 (+2.76%)
At close: October 28 at 4:00:03 PM EDT
280.59 +1.55 (+0.56%)
Overnight: 11:51:49 PM EDT
Trade IQV on Coinbase
IQV Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for IQV

What's happening with IQV?

31m ago
Powered by Yahoo Scout

IQVIA delivered a stronger-than-expected third quarter, with 8% revenue growth, higher bookings, and raised full-year 2026 guidance. Management also highlighted 415 deployed AI agents, while investors continue weighing substantial debt, backlog revisions, and valuation concerns.

Powered by Yahoo Scout
  • Previous Close 271.55
  • Open 270.15
  • Bid --
  • Ask --
  • Day's Range 269.14 - 282.41
  • 52 Week Range 154.50 - 284.50
  • Volume 1,722,524
  • Avg. Volume 1,429,526
  • Market Cap (intraday) 45.986B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 33.95
  • EPS (TTM) 8.22
  • Earnings Date Oct 27, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 308.65
  • Morningstar Rating Rating available with Stock Picks access

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

www.iqvia.com

93,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IQV
23.79%
S&P 500 (^GSPC)
13.13%

1-Year Return

IQV
27.92%
S&P 500 (^GSPC)
12.38%

3-Year Return

IQV
55.07%
S&P 500 (^GSPC)
88.08%

5-Year Return

IQV
8.50%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 4.43B
Earnings 350M
Profit Margin 7.90%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
1B
2B
3B
4B
6.0%
8.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

268.00
308.65 Average
279.04 Current
346.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/28/2026
Analyst JP Morgan
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 295 -> 325

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.05%

  • Return on Assets (ttm)

    5.08%

  • Return on Equity (ttm)

    21.39%

  • Revenue (ttm)

    17.31B

  • Net Income Avi to Common (ttm)

    1.39B

  • Diluted EPS (ttm)

    8.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.42B

  • Total Debt/Equity (mrq)

    240.23%

  • Levered Free Cash Flow (ttm)

    2.06B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: